Evaluation of COVID-19 Patients Who Developed after COVID-19 Vaccination

Authors : Gülsüm Kaya, Pınar Özkan Oskay, Nesrin Kebabcı Mert, Şeyma Trabzon, Zeynep Ergenç, Hasan Ergenç, Osman Karakus, Cengiz Karacaer

Pages : 117-124

Doi:10.34084/bshr.1510840

View : 51 | Download : 37

Publication Date : 2024-08-31

Article Type : Research Paper

Abstract :Aim: The aim of this study is to evaluate the sociodemographic and clinical characteristics of patients with COVID-19 that developed after COVID-19 vaccination. Material and Method: The study was conducted at a state hospital between July 5 and August 5, 2021. Patients who received COVID-19 vaccine, whose SARS-CoV-2 positivity was confirmed by molecular methods, and who were hospitalized for COVID-19 were included. Sociodemographic information and clinical observation results of patients were recorded. Results: 49.09% of the patients were female and the median age was 72.00 [62.00-79.00] years. 70.45% of patients had a chronic disease and 37.27% were constantly using medication. 82.73% of patients received the CoronaVac vaccine and 8.18% received COVID-19 mRNA vaccine; 9.09% had received both vaccines. 66.82% of patients received two doses of COVID-19 vaccine, 26.82% received three doses, 5.45% received one dose and 0.91% received four doses of COVID-19 vaccine. When the infection findings at the time of admission to the hospital are evaluated, the most common symptoms in patients are dyspnea (89.55%), cough (45.45%), weakness (37.73%), malaise (22.27%) and fatigue-exhaustion. (20.00%); 95% of them had COVID-19 findings in their lung imaging reports. 99.55% of patients receive oxygen therapy; 62.73% were connected to mechanical ventilation. 91.82% of patients were receiving steroid treatment, 89.09% were receiving faviripavir treatment, and 98.64% were receiving anticoagulant; 96.82% had received antibiotic treatment. 38.64% of patients were discharged; 61.36% died. Conclusion: It has been observed that the average age of patients who contracted COVID-19 disease after the COVID-19 vaccine was high, they had a high rate of chronic disease, they were vaccinated with hight rate CoronaVac vaccine, and they received a maximum of two doses of vaccine and they did not receive a reminder dose. Mortality and morbidity can be reduced by creating successful vaccination programs as well as protective measures in the fight against COVID-19.
Keywords : Aşı, COVID 19 aşısı, COVID 19 enfeksiyonu, hasta özellikleri